Clinigen Group PLC (CLIN) Given Buy Rating at Peel Hunt
Peel Hunt reiterated their buy rating on shares of Clinigen Group PLC (LON:CLIN) in a research report report published on Wednesday morning. They currently have a GBX 1,000 ($13.05) target price on the stock.
Several other research analysts have also issued reports on the stock. Numis Securities Ltd reiterated a buy rating on shares of Clinigen Group PLC in a research note on Friday, June 24th. Stifel Nicolaus restated a buy rating and set a GBX 800 ($10.44) price objective on shares of Clinigen Group PLC in a research note on Wednesday, July 20th. Five research analysts have rated the stock with a buy rating, Clinigen Group PLC presently has an average rating of Buy and a consensus target price of GBX 856.60 ($11.18).
Clinigen Group PLC (LON:CLIN) traded down 2.48% on Wednesday, reaching GBX 687.50. 215,750 shares of the company’s stock were exchanged. The company’s market cap is GBX 767.24 million. The firm’s 50 day moving average price is GBX 653.09 and its 200 day moving average price is GBX 597.88. Clinigen Group PLC has a 52-week low of GBX 492.75 and a 52-week high of GBX 739.50.
The business also recently declared a dividend, which will be paid on Friday, November 25th. Stockholders of record on Thursday, November 3rd will be issued a dividend of GBX 2.70 ($0.04) per share. This represents a dividend yield of 0.38%. The ex-dividend date is Thursday, November 3rd. This is an increase from Clinigen Group PLC’s previous dividend of $1.30.
Clinigen Group PLC Company Profile
Clinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP).
Receive News & Stock Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related stocks with our FREE daily email newsletter.